Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pacôme Fosse

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
PET Clinics|May 10, 2016
PET in Brain TumorsRoland Hustinx, Pacôme Fosse
PET Clinics|May 10, 2016
Applications of PET and PET/CT in the Evaluation of Infection and Inflammation in the Skeletal SystemGang Cheng, Pacôme Fosse, Hongming Zhuang, et al.
Clinical Nuclear Medicine|January 22, 2013
Unusual uptake of 18FDG by a hepatic adenomaPacôme Fosse, Sylvie Girault, Julien Hoareau, et al.
Plos One|February 8, 2014
[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patientsMammar Hachemi, Olivier Couturier, Laurent Vervueren, et al.
European Journal of Hybrid Imaging|May 22, 2018
<sup>18</sup>F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximabPacôme Fosse, Marie-Joelle Kaiser, Gauthier Namur, et al.
EJNMMI Research|March 6, 2016
For avid glucose tumors, the SUV peak is the most reliable parameter for [(18)F]FDG-PET/CT quantification, regardless of acquisition timeAvigaëlle Sher, Franck Lacoeuille, Pacôme Fosse, et al.
BMC Rheumatology|August 4, 2021
Dissociation between 2-[<sup>18</sup>F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remissionCharline Rinkin, Pacôme Fosse, Olivier Malaise, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
PET Clinics|May 10, 2016
PET in Brain TumorsRoland Hustinx, Pacôme Fosse
PET Clinics|May 10, 2016
Applications of PET and PET/CT in the Evaluation of Infection and Inflammation in the Skeletal SystemGang Cheng, Pacôme Fosse, Hongming Zhuang, et al.
Clinical Nuclear Medicine|January 22, 2013
Unusual uptake of 18FDG by a hepatic adenomaPacôme Fosse, Sylvie Girault, Julien Hoareau, et al.
Plos One|February 8, 2014
[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patientsMammar Hachemi, Olivier Couturier, Laurent Vervueren, et al.
European Journal of Hybrid Imaging|May 22, 2018
<sup>18</sup>F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximabPacôme Fosse, Marie-Joelle Kaiser, Gauthier Namur, et al.
EJNMMI Research|March 6, 2016
For avid glucose tumors, the SUV peak is the most reliable parameter for [(18)F]FDG-PET/CT quantification, regardless of acquisition timeAvigaëlle Sher, Franck Lacoeuille, Pacôme Fosse, et al.
BMC Rheumatology|August 4, 2021
Dissociation between 2-[<sup>18</sup>F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remissionCharline Rinkin, Pacôme Fosse, Olivier Malaise, et al.
Pageof 1